6 results about "Factor XII" patented technology

Disclosed herein are anti-Factor XIIa antibodies and methods of using such for treating diseases associated with Factor XII, including diseases associated with contact system activation, plasma prekallikrein signaling (e.g., hereditary angioedema), and ocular diseases.

The present invention provides compositions and methods for inhibiting thrombosis in subjects at risk of thrombosis, such as those with a genetic, acquired, or environmental risk of thrombosis. [Solution] The present invention provides RNAi agents, such as double-stranded RNAi agents, that target kallikrein B, plasma (Fletcher factor) 1 (KLKB1) gene, factor XII (Hageman factor (F12) gene, or kininogen 1 (KNG1) gene, as well as methods for inhibiting the expression of the KLKB1 gene, F12 gene, and / or KNG1 gene using such RNAi agents, and methods for treating subjects with hereditary angioedema (HAE) and / or contact activation pathway-related disorders.

A method for treating cancer is provided. The method includes administering a combination of a Prolidase, also known as peptidase D (PEPD), in combination with a monoclonal antibody or antigen binding fragment thereof that binds with specificity to a clotting factor, such as Factor XII (FXII). A single dose of the monoclonal antibody is sufficient to enable a therapeutic effect of the PEPD.

The present invention provides monoclonal antibodies that bind to Factor XII (FXII) proteins and methods of use thereof. In various embodiments of the invention, the antibodies are fully human antibodies that bind to FXII and an activated form of FXII (FXIIa). In some embodiments, the antibodies of the invention may be used to inhibit or neutralize the activity of FXII, thereby providing a means for the treatment or prevention of diseases, disorders or conditions associated with thrombosis in humans.

The present application relates to a liquid formulation comprising at least 100 mg / ml of a protein comprising an antigen-binding domain that binds to FXII (and / or its activated form), an organic acid buffer, a non-ionic surfactant, and an amino acid stabilizer, wherein the formulation has a pH of 5.0-6.5 and a viscosity of less than 30 mPa*s at 20° C. An exemplary formulation comprises the specific factor XII antibody 3F7 in a formulation comprising a histidine buffer, a polysorbate 80 surfactant, and the amino acid stabilizers arginine and proline.